NCT04867980 - A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

May 9, 2016

Study Completion Date

May 9, 2016

Conditions

Healthy Volunteers

Interventions

DRUG

ACP-196

Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.

DRUG

Moxifloxacin 400 mg

Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.

DRUG

Placebo

Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.

Trial Locations (1)

85283

Celerion, Tempe